AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaInformation ScienceHealth Care
Burkitt LymphomaLymphomaLymphoma, B-CellLymphoma, Non-HodgkinLymphoma, Large B-Cell, DiffuseLymphoma, T-CellHerpesvirus 4, HumanLymphoma, FollicularLymphoma, AIDS-RelatedTranslocation, GeneticChromosomes, Human, 6-12 and XLymphoma, B-Cell, Marginal ZoneEpstein-Barr Virus Nuclear AntigensChromosomes, Human, 13-15Glutamate FormimidoyltransferaseGenes, mycProto-Oncogene Proteins c-mycB-LymphocytesEpstein-Barr Virus InfectionsLymphoma, Mantle-CellLymphoma, T-Cell, CutaneousHodgkin DiseaseLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, AnaplasticChromosomes, Human, Pair 14VincristineTumor Cells, CulturedGerminal CenterOncogenesAntibodies, Monoclonal, Murine-DerivedCyclophosphamideIn Situ Hybridization, FluorescenceAntigens, CD20Chromosomes, Human, 1-3Genes, Immunoglobulin Heavy ChainCell Line, TumorImmunophenotypingImmunoglobulin Heavy ChainsCell LineSesquiterpenes, GuaianeLeukemia, B-CellDoxorubicinGene RearrangementSesquiterpenes, EudesmaneChromosomes, Human, Pair 8NeprilysinCytogeneticsAntineoplastic Combined Chemotherapy ProtocolsLymphoma, Large-Cell, ImmunoblasticViral Matrix ProteinsHLA-A11 AntigenGenes, mybImmunohistochemistryGene Expression Regulation, NeoplasticProto-Oncogene Proteins c-bcl-2Genes, bcl-2PlasmacytomaCytarabineBase SequenceApoptosisAntibodies, MonoclonalTanacetum partheniumFlow CytometryVirus LatencyAntigens, ViralPrednisoneInhibitor of Differentiation ProteinsLymphoproliferative DisordersDNA, NeoplasmGenes, ImmunoglobulinChromosome BandingKaryotypingTreatment OutcomeMethotrexateReceptors, Antigen, B-CellCell Transformation, ViralNeoplasm ProteinsAntineoplastic AgentsEtoposideMolecular Sequence DataProto-OncogenesLeukemia, LymphoidPrognosisLymphocytesRemission InductionLymphoma, Extranodal NK-T-CellCell Transformation, NeoplasticTumor Markers, BiologicalTranscription, GeneticCell Line, TransformedPolymerase Chain ReactionGene Expression Regulation, ViralDNA, ViralChaperonin Containing TCP-1BiopsyHybrid CellsVirus ActivationNational Cancer Institute (U.S.)
Burkitt Lymphoma: A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.Lymphoma, B-Cell: A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.Lymphoma, Large B-Cell, Diffuse: Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.Lymphoma, T-Cell: A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.Herpesvirus 4, Human: The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies.Lymphoma, Follicular: Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.Lymphoma, AIDS-Related: B-cell lymphoid tumors that occur in association with AIDS. Patients often present with an advanced stage of disease and highly malignant subtypes including BURKITT LYMPHOMA; IMMUNOBLASTIC LARGE-CELL LYMPHOMA; PRIMARY EFFUSION LYMPHOMA; and DIFFUSE, LARGE B-CELL, LYMPHOMA. The tumors are often disseminated in unusual extranodal sites and chromosomal abnormalities are frequently present. It is likely that polyclonal B-cell lymphoproliferation in AIDS is a complex result of EBV infection, HIV antigenic stimulation, and T-cell-dependent HIV activation.Translocation, Genetic: A type of chromosome aberration characterized by CHROMOSOME BREAKAGE and transfer of the broken-off portion to another location, often to a different chromosome.Chromosomes, Human, 6-12 and X: The medium-sized, submetacentric human chromosomes, called group C in the human chromosome classification. This group consists of chromosome pairs 6, 7, 8, 9, 10, 11, and 12 and the X chromosome.Lymphoma, B-Cell, Marginal Zone: Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire mucosa-associated lymphoid tissue (MALT) type as a result of an immunologically mediated disorder.Epstein-Barr Virus Nuclear Antigens: Nuclear antigens encoded by VIRAL GENES found in HUMAN HERPESVIRUS 4. At least six nuclear antigens have been identified.Chromosomes, Human, 13-15: The medium-sized, acrocentric human chromosomes, called group D in the human chromosome classification. This group consists of chromosome pairs 13, 14, and 15.Glutamate Formimidoyltransferase: A PYRIDOXAL PHOSPHATE-containing enzyme that catalyzes the transfer of a formyl group from L-GLUTAMATE to N-formimidoyl-L-glutamate and TETRAHYDROFOLATE. This enzyme may also catalyze formyl transfer from 5-formyltetrahydrofolate to L-GLUTAMATE. This enzyme was formerly categorized as EC 2.1.2.6.Genes, myc: Family of retrovirus-associated DNA sequences (myc) originally isolated from an avian myelocytomatosis virus. The proto-oncogene myc (c-myc) codes for a nuclear protein which is involved in nucleic acid metabolism and in mediating the cellular response to growth factors. Truncation of the first exon, which appears to regulate c-myc expression, is crucial for tumorigenicity. The human c-myc gene is located at 8q24 on the long arm of chromosome 8.Proto-Oncogene Proteins c-myc: Cellular DNA-binding proteins encoded by the c-myc genes. They are normally involved in nucleic acid metabolism and in mediating the cellular response to growth factors. Elevated and deregulated (constitutive) expression of c-myc proteins can cause tumorigenesis.B-Lymphocytes: Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.Epstein-Barr Virus Infections: Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).Lymphoma, Mantle-Cell: A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).Lymphoma, T-Cell, Cutaneous: A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.Hodgkin Disease: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.Lymphoma, T-Cell, Peripheral: A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.Lymphoma, Large-Cell, Anaplastic: A systemic, large-cell, non-Hodgkin, malignant lymphoma characterized by cells with pleomorphic appearance and expressing the CD30 ANTIGEN. These so-called "hallmark" cells have lobulated and indented nuclei. This lymphoma is often mistaken for metastatic carcinoma and MALIGNANT HISTIOCYTOSIS.Chromosomes, Human, Pair 14: A specific pair of GROUP D CHROMOSOMES of the human chromosome classification.Vincristine: An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)Tumor Cells, Cultured: Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.Germinal Center: The activated center of a lymphoid follicle in secondary lymphoid tissue where B-LYMPHOCYTES are stimulated by antigens and helper T cells (T-LYMPHOCYTES, HELPER-INDUCER) are stimulated to generate memory cells.Oncogenes: Genes whose gain-of-function alterations lead to NEOPLASTIC CELL TRANSFORMATION. They include, for example, genes for activators or stimulators of CELL PROLIFERATION such as growth factors, growth factor receptors, protein kinases, signal transducers, nuclear phosphoproteins, and transcription factors. A prefix of "v-" before oncogene symbols indicates oncogenes captured and transmitted by RETROVIRUSES; the prefix "c-" before the gene symbol of an oncogene indicates it is the cellular homolog (PROTO-ONCOGENES) of a v-oncogene.Antibodies, Monoclonal, Murine-Derived: Antibodies obtained from a single clone of cells grown in mice or rats.Cyclophosphamide: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.In Situ Hybridization, Fluorescence: A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.Antigens, CD20: Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.Chromosomes, Human, 1-3: The large, metacentric human chromosomes, called group A in the human chromosome classification. This group consists of chromosome pairs 1, 2, and 3.Genes, Immunoglobulin Heavy Chain: Genes and gene segments encoding the IMMUNOGLOBULIN HEAVY CHAINS. Gene segments of the heavy chain genes are symbolized V (variable), D (diversity), J (joining), and C (constant).Cell Line, Tumor: A cell line derived from cultured tumor cells.Immunophenotyping: Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.Immunoglobulin Heavy Chains: The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa.Cell Line: Established cell cultures that have the potential to propagate indefinitely.Sesquiterpenes, Guaiane: SESQUITERPENES cyclized into two adjoining rings, one being 7-carbons and the other is 5-carbons.Leukemia, B-Cell: A malignant disease of the B-LYMPHOCYTES in the bone marrow and/or blood.Doxorubicin: Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.Gene Rearrangement: The ordered rearrangement of gene regions by DNA recombination such as that which occurs normally during development.Sesquiterpenes, Eudesmane: SESQUITERPENES cyclized into two adjoining cyclohexane rings but with a different configuration from the ARTEMISININS.Chromosomes, Human, Pair 8: A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.Neprilysin: Enzyme that is a major constituent of kidney brush-border membranes and is also present to a lesser degree in the brain and other tissues. It preferentially catalyzes cleavage at the amino group of hydrophobic residues of the B-chain of insulin as well as opioid peptides and other biologically active peptides. The enzyme is inhibited primarily by EDTA, phosphoramidon, and thiorphan and is reactivated by zinc. Neprilysin is identical to common acute lymphoblastic leukemia antigen (CALLA Antigen), an important marker in the diagnosis of human acute lymphocytic leukemia. There is no relationship with CALLA PLANT.Cytogenetics: A subdiscipline of genetics which deals with the cytological and molecular analysis of the CHROMOSOMES, and location of the GENES on chromosomes, and the movements of chromosomes during the CELL CYCLE.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Lymphoma, Large-Cell, Immunoblastic: Malignant lymphoma characterized by the presence of immunoblasts with uniformly round-to-oval nuclei, one or more prominent nucleoli, and abundant cytoplasm. This class may be subdivided into plasmacytoid and clear-cell types based on cytoplasmic characteristics. A third category, pleomorphous, may be analogous to some of the peripheral T-cell lymphomas (LYMPHOMA, T-CELL, PERIPHERAL) recorded in both the United States and Japan.Viral Matrix Proteins: Proteins associated with the inner surface of the lipid bilayer of the viral envelope. These proteins have been implicated in control of viral transcription and may possibly serve as the "glue" that binds the nucleocapsid to the appropriate membrane site during viral budding from the host cell.HLA-A11 Antigen: A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*11 allele family.Genes, myb: Retrovirus-associated DNA sequences (v-myb) originally isolated from the avian myeloblastosis and E26 leukemia viruses. The proto-oncogene c-myb codes for a nuclear protein involved in transcriptional regulation and appears to be essential for hematopoietic cell proliferation. The human myb gene is located at 6q22-23 on the short arm of chromosome 6. This is the point of break in translocations involved in T-cell acute lymphatic leukemia and in some ovarian cancers and melanomas. (From Ibelgaufts, Dictionary of Cytokines, 1995).Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Gene Expression Regulation, Neoplastic: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.Proto-Oncogene Proteins c-bcl-2: Membrane proteins encoded by the BCL-2 GENES and serving as potent inhibitors of cell death by APOPTOSIS. The proteins are found on mitochondrial, microsomal, and NUCLEAR MEMBRANE sites within many cell types. Overexpression of bcl-2 proteins, due to a translocation of the gene, is associated with follicular lymphoma.Genes, bcl-2: The B-cell leukemia/lymphoma-2 genes, responsible for blocking apoptosis in normal cells, and associated with follicular lymphoma when overexpressed. Overexpression results from the t(14;18) translocation. The human c-bcl-2 gene is located at 18q24 on the long arm of chromosome 18.Plasmacytoma: Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites.Cytarabine: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)Base Sequence: The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.Apoptosis: One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Tanacetum parthenium: An aromatic perennial plant species that has been used to treat migraines, arthritis, and as a febrifuge. It contains TANNINS, volatile oils (OILS, ESSENTIAL), and sesquiterpene lactones, especially parthenolide.Flow Cytometry: Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.Virus Latency: The ability of a pathogenic virus to lie dormant within a cell (latent infection). In eukaryotes, subsequent activation and viral replication is thought to be caused by extracellular stimulation of cellular transcription factors. Latency in bacteriophage is maintained by the expression of virally encoded repressors.Antigens, Viral: Substances elaborated by viruses that have antigenic activity.Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.Inhibitor of Differentiation Proteins: Inhibitor of differentiation proteins are negative regulators of BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS. They inhibit CELL DIFFERENTIATION and induce CELL PROLIFERATION by modulating different CELL CYCLE regulators.Lymphoproliferative Disorders: Disorders characterized by proliferation of lymphoid tissue, general or unspecified.DNA, Neoplasm: DNA present in neoplastic tissue.Genes, Immunoglobulin: Genes encoding the different subunits of the IMMUNOGLOBULINS, for example the IMMUNOGLOBULIN LIGHT CHAIN GENES and the IMMUNOGLOBULIN HEAVY CHAIN GENES. The heavy and light immunoglobulin genes are present as gene segments in the germline cells. The completed genes are created when the segments are shuffled and assembled (B-LYMPHOCYTE GENE REARRANGEMENT) during B-LYMPHOCYTE maturation. The gene segments of the human light and heavy chain germline genes are symbolized V (variable), J (joining) and C (constant). The heavy chain germline genes have an additional segment D (diversity).Chromosome Banding: Staining of bands, or chromosome segments, allowing the precise identification of individual chromosomes or parts of chromosomes. Applications include the determination of chromosome rearrangements in malformation syndromes and cancer, the chemistry of chromosome segments, chromosome changes during evolution, and, in conjunction with cell hybridization studies, chromosome mapping.Karyotyping: Mapping of the KARYOTYPE of a cell.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Methotrexate: An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.Receptors, Antigen, B-Cell: IMMUNOGLOBULINS on the surface of B-LYMPHOCYTES. Their MESSENGER RNA contains an EXON with a membrane spanning sequence, producing immunoglobulins in the form of type I transmembrane proteins as opposed to secreted immunoglobulins (ANTIBODIES) which do not contain the membrane spanning segment.Cell Transformation, Viral: An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.Neoplasm Proteins: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Etoposide: A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Proto-Oncogenes: Normal cellular genes homologous to viral oncogenes. The products of proto-oncogenes are important regulators of biological processes and appear to be involved in the events that serve to maintain the ordered procession through the cell cycle. Proto-oncogenes have names of the form c-onc.Leukemia, Lymphoid: Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Lymphocytes: White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.Remission Induction: Therapeutic act or process that initiates a response to a complete or partial remission level.Lymphoma, Extranodal NK-T-Cell: An extranodal neoplasm, usually possessing an NK-cell phenotype and associated with EPSTEIN-BARR VIRUS. These lymphomas exhibit a broad morphologic spectrum, frequent necrosis, angioinvasion, and most commonly present in the midfacial region, but also in other extranodal sites.Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.Tumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Transcription, Genetic: The biosynthesis of RNA carried out on a template of DNA. The biosynthesis of DNA from an RNA template is called REVERSE TRANSCRIPTION.Cell Line, Transformed: Eukaryotic cell line obtained in a quiescent or stationary phase which undergoes conversion to a state of unregulated growth in culture, resembling an in vitro tumor. It occurs spontaneously or through interaction with viruses, oncogenes, radiation, or drugs/chemicals.Polymerase Chain Reaction: In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.Gene Expression Regulation, Viral: Any of the processes by which cytoplasmic factors influence the differential control of gene action in viruses.DNA, Viral: Deoxyribonucleic acid that makes up the genetic material of viruses.Chaperonin Containing TCP-1: A group II chaperonin found in eukaryotic CYTOSOL. It is comprised of eight subunits with each subunit encoded by a separate gene. This chaperonin is named after one of its subunits which is a T-COMPLEX REGION-encoded polypeptide.Biopsy: Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.Hybrid Cells: Any cell, other than a ZYGOTE, that contains elements (such as NUCLEI and CYTOPLASM) from two or more different cells, usually produced by artificial CELL FUSION.Virus Activation: The mechanism by which latent viruses, such as genetically transmitted tumor viruses (PROVIRUSES) or PROPHAGES of lysogenic bacteria, are induced to replicate and then released as infectious viruses. It may be effected by various endogenous and exogenous stimuli, including B-cell LIPOPOLYSACCHARIDES, glucocorticoid hormones, halogenated pyrimidines, IONIZING RADIATION, ultraviolet light, and superinfecting viruses.National Cancer Institute (U.S.): Component of the NATIONAL INSTITUTES OF HEALTH. Through basic and clinical biomedical research and training, it conducts and supports research with the objective of cancer prevention, early stage identification and elimination. This Institute was established in 1937.

Epstein-barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma. (1/1897)

Loss of the Epstein-Barr virus (EBV) genome from Akata Burkitt lymphoma (BL) cells is coincident with a loss of malignant phenotype, despite the fact that Akata and other EBV-positive BL cells express a restricted set of EBV gene products (type I latency) that are not known to overtly affect cell growth. Here we demonstrate that reestablishment of type I latency in EBV-negative Akata cells restores tumorigenicity and that tumorigenic potential correlates with an increased resistance to apoptosis under growth-limiting conditions. The antiapoptotic effect of EBV was associated with a higher level of Bcl-2 expression and an EBV-dependent decrease in steady-state levels of c-MYC protein. Although the EBV EBNA-1 protein is expressed in all EBV-associated tumors and is reported to have oncogenic potential, enforced expression of EBNA-1 alone in EBV-negative Akata cells failed to restore tumorigenicity or EBV-dependent down-regulation of c-MYC. These data provide direct evidence that EBV contributes to the tumorigenic potential of Burkitt lymphoma and suggest a novel model whereby a restricted latency program of EBV promotes B-cell survival, and thus virus persistence within an immune host, by selectively targeting the expression of c-MYC.  (+info)

Differential expression and phosphorylation of CTCF, a c-myc transcriptional regulator, during differentiation of human myeloid cells. (2/1897)

CTCF is a transcriptional repressor of the c-myc gene. Although CTCF has been characterized in some detail, there is very little information about the regulation of CTCF activity. Therefore we investigated CTCF expression and phosphorylation during induced differentiation of human myeloid leukemia cells. We found that: (i) both CTCF mRNA and protein are down-regulated during terminal differentiation in most cell lines tested; (ii) CTCF down-regulation is retarded and less pronounced than that of c-myc; (iii) CTCF protein is differentially phosphorylated and the phosphorylation profiles depend on the differentiation pathway. We concluded that CTCF expression and activity is controlled at transcriptional and post-transcriptional levels.  (+info)

Involvement of wiskott-aldrich syndrome protein in B-cell cytoplasmic tyrosine kinase pathway. (3/1897)

Bruton's tyrosine kinase (Btk) has been shown to play a role in normal B-lymphocyte development. Defective expression of Btk leads to human and murine immunodeficiencies. However, the exact role of Btk in the cytoplasmic signal transduction in B cells is still unclear. This study represents a search for the substrate for Btk in vivo. We identified one of the major phosphoproteins associated with Btk in the preB cell line NALM6 as the Wiskott-Aldrich syndrome protein (WASP), the gene product responsible for Wiskott-Aldrich syndrome, which is another hereditary immunodeficiency with distinct abnormalities in hematopoietic cells. We demonstrated that WASP was transiently tyrosine-phosphorylated after B-cell antigen receptor cross-linking on B cells, suggesting that WASP is located downstream of cytoplasmic tyrosine kinases. An in vivo reconstitution system demonstrated that WASP is physically associated with Btk and can serve as the substrate for Btk. A protein binding assay suggested that the tyrosine-phosphorylation of WASP alters the association between WASP and a cellular protein. Furthermore, identification of the phosphorylation site of WASP in reconstituted cells allowed us to evaluate the catalytic specificity of Btk, the exact nature of which is still unknown.  (+info)

Analysis of the interaction of monoclonal antibodies with surface IgM on neoplastic B-cells. (4/1897)

In vitro studies identified three Burkitts lymphoma cell lines, Ramos, MUTU-I and Daudi, that were growth inhibited by anti-IgM antibody. However, only Ramos and MUTU-I were sensitive to monoclonal antibodies (mAb) recognizing the Fc region of surface IgM (anti-Fc mu). Experiments using anti-Fc mu mAb (single or non-crossblocking pairs), polyclonal anti-mu Ab, and hyper-crosslinking with a secondary layer of Ab, showed that growth inhibition of B-cell lines was highly dependent on the extent of IgM crosslinking. This was confirmed by using Fab', F(ab')2 and F(ab')3 derivatives from anti-Fc mu mAb, where increasing valency caused corresponding increases in growth arrest and apoptosis, presumably as a result of more efficient BCR-crosslinking on the cell surface. The ability of a single mAb to induce growth arrest was highly dependent on epitope specificity, with mAb specific for the Fc region (C mu2-C mu4 domains) being much more effective than those recognizing the Fab region (anti-L chain, anti-Id and anti-Fd mu, or C mu1). Only when hyper-crosslinked with polyclonal anti-mouse IgG did the latter result in appreciable growth inhibition. Binding studies showed that these differences in function were not related to differences in the affinity, but probably related to intrinsic crosslinking capacity of mAb.  (+info)

Differential responses to CD40 ligation among Burkitt lymphoma lines that are uniformly responsive to Epstein-Barr virus latent membrane protein 1. (5/1897)

Ligation of CD40 on the surface of B cells induces multiple phenotypic effects, many of which are mimicked by the EBV latent membrane protein 1 (LMP1) through its interaction with downstream components of the CD40 signaling pathway. Because the effects of LMP1 have been most closely studied in human Burkitt Lymphoma (BL) cell lines retaining a tumor biopsy-like phenotype in vitro, we have examined the response of a panel of such lines to CD40 ligation. Two distinct patterns of response were observed that were unrelated to the surface level of CD40 or to the EBV genome status of the lines. Following exposure to either CD40-specific mAbs or the soluble trimeric ligand (sCD40L), high responder (HR) lines showed rapid aggregation, activation of NF-kappa B, up-regulation of cell surface markers ICAM-1/CD54 and Fas/CD95, and growth inhibition. Aggregation was seen at lower doses than those required to elicit the other effects. By contrast, low responder (LR) lines showed no detectable response to CD40 mAbs, while their responses to sCD40L were limited to activation of NF-kappa B and up-regulation of CD95 only. However, in transfection experiments, LMP1 uniformly induced the full spectrum of phenotypic effects in both HR and LR lines. We conclude that some BL cell lines show a highly restricted response to CD40 ligation but remain fully susceptible to LMP1.  (+info)

Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases. (6/1897)

Human antibody responses to latent membrane protein 1 (LMP1) in patients with Epstein-Barr virus (EBV)-related disease syndromes were analyzed in detail. Only by immunoblot analysis with purified recombinant LMP1 and by IFA on recombinant LMP1-expressing insect cells could human antibodies directed against LMP1 be detected. Low serum levels of LMP1-directed antibodies could be detected in 3 of 8 EBV-positive Hodgkin's disease patients, 3 of 40 nasopharyngeal carcinoma patients, 2 of 23 Burkitt's lymphoma patients, and 1 of 27 non-Burkitt's lymphoma patients. No LMP1-directed antibodies could be detected in healthy EBV carriers, infectious mononucleosis patients, or patients with chronic EBV disease. All sera contained significant levels of EBV antibodies directed against the immunodominant EBV proteins and peptides. From this study, it can be concluded that LMP1 is a protein with a very low immunogenicity for the humoral immune response in humans.  (+info)

Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo. (7/1897)

The consistent presence of EBV genomes in certain tumor types (in particular, AIDS-related central nervous system lymphomas and nasopharyngeal carcinomas) may allow novel, EBV-based targeting strategies. Tumors contain the latent (transforming) form of EBV infection. However, expression of either of the EBV immediate-early proteins, BZLF1 and BRLF1, is sufficient to induce lytic EBV infection, resulting in death of the host cell. We have constructed replication-deficient adenovirus vectors expressing the BZLF1 or BRLF1 immediate-early genes and examined their utility for killing latently infected lymphoma cells in vitro and in vivo. We show that both the BZLF1 and BRLF1 vectors efficiently induce lytic EBV infection in Jijoye cells (an EBV-positive Burkitt lymphoma cell line). Furthermore, lytic EBV infection converts the antiviral drug, ganciclovir (GCV), into a toxic (phosphorylated) form, which inhibits cellular as well as viral DNA polymerase. When Jijoye cells are infected with the BZLF1 or BRLF1 adenovirus vectors in the presence of GCV, viral reactivation is induced, but virus replication is inhibited (thus preventing the release of infectious EBV particles); yet cells are still efficiently killed. Finally, we demonstrate that the BZLF1 and BRLF1 adenovirus vectors induce lytic EBV infection when they are directly inoculated into Jijoye cell tumors grown in severe combined immunodeficiency mice. These results suggest that induction of lytic EBV infection in tumors, in combination with GCV, may be an effective strategy for treating EBV-associated malignancies.  (+info)

Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma. (8/1897)

In Burkitt's lymphoma (BL) cells the proto-oncogene c-myc is juxtaposed to one of the immunoglobulin (Ig) loci on chromosomes 2, 14, or 22. The c-myc gene becomes transcriptionally activated as a consequence of the chromosomal translocation and shows preferential usage of promoter P1 over P2, a phenomenon referred to as promoter shift. In order to define the responsible regulatory elements within the Ig lambda locus, we studied the effect of the human Ig lambda enhancer (HuE lambda) on c-myc expression after stable transfection into BL cells. A 12 kb genomic fragment encompassing HuE lambda, but not HuE lambda alone, strongly activated c-myc expression and induced the promoter shift. To identify additional elements involved in c-myc deregulation, we mapped DNaseI hypersensitive sites within the 12 kb lambda fragment on the construct. Besides one hypersensitive site corresponding to HuE lambda, three additional sites were detected. Two of these elements displayed enhancer activity after transient transfection. The third element did not activate c-myc transcription, but was required for full c-myc activation and promoter shift. Deletion analyses of the c-myc promoter identified the immediate promoter region as sufficient for activation by the Ig lambda. locus, but also revealed that induction of the promoter shift requires additional upstream elements.  (+info)

Burkitt Lymphoma Archives | Morgan Adams FoundationBurkitt Lymphoma Archives | Morgan Adams Foundation
What is Burkitt Lymphoma?. Burkitt lymphoma is a form of non-Hodgkins lymphoma which is a type of cancer that starts in the b-cells. Burkitt lymphoma is one of the fastest growing tumors. Burkitt lymphoma attacks the immune system and is fatal if not treated in a timely manner. There are three types of Burkitts lymphoma endemic, sporadic, and immunodeficiency- associated.. What causes Burkitt lymphoma? Who is affected?. The exact cause of Burkitt lymphoma is unknown, but there are factors associated with the disease such as Epstein-Barr. Individuals who are immunosuppressed have a higher risk factor for Burkitt lymphoma. Burkitt lymphoma primarily affects African children, and malaria may make children more vulnerable.. What are the symptoms of Burkitt lymphoma?. There are many symptoms associated with Burkitt lymphoma, including:. ...
Burkitt-like lymphoma in an English child: Characterisation of tumour biopsy cells and of the derived tumour cell lineBurkitt-like lymphoma in an English child: Characterisation of tumour biopsy cells and of the derived tumour cell line
An eight year old English boy presented with an abdominal undifferentiated Burkitt-like lymphoma. Lymphoma cells from ascitic fluid were cultured on a human embryo fibroblast feeder layer and, after a short lag period, a cell line (DH-BL) was established which, like the original tumour, was both negative for the Epstein-Barr nuclear antigen (EBNA) and expressed a monoclonal pattern of surface immunoglobulin (alpha lambda). DH-BL also possessed the Burkitt-related 8:14 chromosome translocation in all metaphases analysed; no other chromosomal abnormalities were present. The cell surface phenotype of the original biopsy cells and the cultured tumour cells in early passage were investigated using a panel of monoclonal antibodies to B lineage-associated antigens. These antibodies had recently been used to characterise African endemic Burkitts lymphoma (BL) biopsy cells and their derived cell lines. The cell surface phenotype of this English EBNA negative Burkitt-like lymphoma biopsy was ...
Burkitt Lymphoma and Burkitt-like Lymphoma: Practice Essentials, Background, Etiology and PathophysiologyBurkitt Lymphoma and Burkitt-like Lymphoma: Practice Essentials, Background, Etiology and Pathophysiology
Burkitt lymphoma (BL) (or small noncleaved cell lymphoma) is one of the highly aggressive B-cell non-Hodgkin lymphomas (NHL) that is characterized by the translocation and deregulation of the c-myc gene on chromosome 8. Malignant small noncleaved lymphoma, a historical term, was used to describe this disease in patients presenting with a soli...
Integrative microRNA and mRNA deep-sequencing expression profiling in endemic Burkitt lymphoma | BMC Cancer | Full TextIntegrative microRNA and mRNA deep-sequencing expression profiling in endemic Burkitt lymphoma | BMC Cancer | Full Text
Burkitt lymphoma (BL) is characterized by overexpression of the c-myc oncogene, which in the vast majority of cases is a consequence of an IGH/MYC translocation. While myc is the seminal event, BL is a complex amalgam of genetic and epigenetic changes causing dysregulation of both coding and non-coding transcripts. Emerging evidence suggest that abnormal modulation of mRNA transcription via miRNAs might be a significant factor in lymphomagenesis. However, the alterations in these miRNAs and their correlations to their putative mRNA targets have not been extensively studied relative to normal germinal center (GC) B cells. Using more sensitive and specific transcriptome deep sequencing, we compared previously published small miRNA and long mRNA of a set of GC B cells and eBL tumors. MiRWalk2.0 was used to identify the validated target genes for the deregulated miRNAs, which would be important for understanding the regulatory networks associated with eBL development. We found 211 differentially expressed
Burkitts lymphomasBurkitt's lymphomas
Burkitt are highly aggressive lymphomas. As such, the goal of treatment is usually to cure the disease with aggressive therapy. From OncologyChannel: Small noncleaved cell lymphoma (SNCL) is a classification that, in general, has been replaced by the terms Burkitt lymphoma and Burkitt-like (or non-Burkitt) lymphoma. In children, most SNCLs are Burkitt lymphomas, whereas most adult SNCLs are Burkitt-like lymphomas. Burkitts lymphoma tends to occur most often in children and in adults with compromised immune systems. There are three distinct forms of this disease: endemic, sporadic, and immunodeficient.. ...
Raji membrane lysate (ab30126) | AbcamRaji membrane lysate (ab30126) | Abcam
Buy our Raji (human Burkitts lymphoma cell line) membrane lysate, tumor cell line. ab30126 has been validated in western blot. Abcam now offers…
Raji lysate (ab30124) | AbcamRaji lysate (ab30124) | Abcam
Buy our Raji (human Burkitts lymphoma cell line) whole cell lysate, tumor cell line. ab30124 has been validated in western blot. Abcam now offers…
MAB6690 - R&D Systems IRAK2 antibody | AntibodypediaMAB6690 - R&D Systems IRAK2 antibody | Antibodypedia
Detection of Human IRAK2 by Western Blot. Western blot shows lysates of Jurkat human acute T cell leukemia cell line, Raji human Burkitts lymphoma cell line, K562 human chronic myelogenous leukemia cell line, and HeLa human cervical epithelial carcinoma cell line. PVDF Membrane was probed with 0.5 µg/mL of Human IRAK2 Monoclonal Antibody (Catalog # MAB6690) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for IRAK2 at approximately 65 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1 ...
Matthew D. Scharff, M.D. -- Research Interest | Department of Cell Biology | Albert Einstein College of MedicineMatthew D. Scharff, M.D. -- Research Interest | Department of Cell Biology | Albert Einstein College of Medicine
Our laboratory is studying how antibody-forming cells respond to antigen by undergoing somatic hypermutation and class switch recombination so that they can produce higher affinity antibodies with more useful effector functions. The molecular and biochemical mechanisms of antibody variable region hypermutation and class switch recombination is being studied in mice that have mutations in various repair proteins in collaboration with Dr. Winfried Edelmann. In order to examine detailed molecular mechanisms, we are also studying how mutation is targeted to antibody genes and some oncogenes in human Burkitts lymphoma cell lines which are undergoing variable region mutation in culture. These cell lines and genetically defective mice are being used to study the role of activation induced deaminase (AID), mismatch repair and error prone polymerases in the variable region hypermutation and isotype switching. The analysis of these events also involves the examination of AID activity biochemically and, ...
The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells | Molecular Cancer | Full TextThe novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells | Molecular Cancer | Full Text
Migration of metastatic tumor cells from the bloodstream into lymph nodes is thought to be facilitated by expression of the chemokine receptors CCR7, CXCR4 and, for B cell-derived tumors, CXCR5. Expression of their respective chemokine ligands (CCL19, CCL21, CXCL12 and CXCL13) by endothelial cells inside the lymph nodes facilitates the trans-endothelial migration (TEM) of these cells through high endothelial venules into the lymph node parenchyma. It is known that CXCR7, a second CXCL12 receptor, regulates TEM of CXCR4+CXCR7+ tumor cells towards a CXCL12 source. In this study, we set out to assess the potential stimulation by CXCL12 of tumor cell TEM towards other chemokines and whether CXCR7 might be able to regulate such effects. The human Burkitts lymphoma cell line NC-37, which expresses CXCR4, CXCR5, CXCR7 and CCR7, was selected as a model system. TEM of these cells through a human HUVEC endothelial cell monolayer was used as the main model system for these studies. Regulation of their TEM
Plus itPlus it
The nuclear enzyme poly(ADP-ribose) polymerase (PADPRP) is thought to play a role in DNA recombination, replication, and repair. In view of the implication of these processes in tumorigenesis, and based on preliminary evidence which indicated the presence of an extraneous polymorphic restriction fragment for murine PADPRP loci in strains of mice susceptible to plasmacytomas, we investigated correlations between the restriction fragment length polymorphism of the PADPRP gene(s) and human Burkitt lymphoma. No increase in the frequency of polymorphisms on chromosome 1 (containing the active gene) or on chromosome 14 (a pseudogene) was observed. However, restriction fragment length polymorphism analysis of PADPRP sequences on chromosome 13 (either a processed pseudogene or a gene with extensive identity to PADPRP) revealed that of 19 DNA samples derived from endemic Burkitt lymphoma all contained at least one copy of a rare allele (B). Simple two-allele (A/B) polymorphisms in this PADPRP-like locus ...
CD19 monoclonal antibody, clone LT19 (Biotin) - (MAB4370) - Products - AbnovaCD19 monoclonal antibody, clone LT19 (Biotin) - (MAB4370) - Products - Abnova
Mouse monoclonal antibody raised against native CD19. Native purified CD19 from Daudi human Burkitt lymphoma cell line. (MAB4370) - Products - Abnova
Histone deacetylase 6 activity is critical for the metastasis of Burkitts lymphoma cells | Cancer Cell International | Full...Histone deacetylase 6 activity is critical for the metastasis of Burkitt's lymphoma cells | Cancer Cell International | Full...
Burkitts lymphoma is an aggressive malignancy with high risk of metastasis to extranodal sites, such as bone marrow and central nervous system. The prognosis of metastatic Burkitts lymphoma is poor. Here we sought to identify a role of histone deacetylase 6 (HDAC6) in the metastasis of Burkitts lymphoma cells. Burkitts lymphoma cells were pharmacologically treated with niltubacin, tubacin or sodium butyrate (NaB) or transfected with siRNAs to knock down the expression of HDAC6. Cell migration and invasion ability were measured by transwell assay, and cell cycle progression was analyzed by flow cytometry. Cell adhesion and proliferation was determined by CellTiter-Glo luminescent cell viability assay kit. Cell morphological alteration and microtubule stability were analyzed by immunofluorescence staining. Effect of niltubacin, tubacin and NaB on acetylated tubulin and siRNA efficacy were measured by western blotting. Suppression of histone deacetylase 6 activity significantly compromised the
Quantitative profiling of housekeeping and Epstein-Barr virus gene transcription in Burkitt lymphoma cell lines using an...Quantitative profiling of housekeeping and Epstein-Barr virus gene transcription in Burkitt lymphoma cell lines using an...
BURKITT-LYMPHOM (PATHOLOGIE); ZELLLINIEN + ZELLLINIENISOLIERUNG (CYTOLOGISCHE METHODEN); EPSTEIN-BARR-VIRUS (VIROLOGIE); TRANSKRIPTION (MOLEKULARE GENETIK); DNA-MIKROARRAY TECHNOLOGIE; BURKITT LYMPHOMA (PATHOLOGY); CELL LINES + CELL LINE ISOLATION (CYTOLOGICAL METHODS); EPSTEIN-BARR-VIRUS (VIROLOGY); TRANSCRIPTION (MOLECULAR GENETICS); DNA ...
Correction: Exosomes Derived from Burkitts Lymphoma Cell Lines Induce Proliferation, Differentiation, and Class-Switch...Correction: Exosomes Derived from Burkitt's Lymphoma Cell Lines Induce Proliferation, Differentiation, and Class-Switch...
Gutzeit, C., N. Nagy, M. Gentile, K. Lyberg, J. Gumz, H. Vallhov, I. Puga, E. Klein, S. Gabrielsson, A. Cerutti, and A. Scheynius. 2014. Exosomes derived from Burkitts lymphoma cell lines induce proliferation, differentiation, and class-switch recombination in B cells. J. Immunol. 192: 5852-5862.. In the published version of Fig. 6A, the FACS dotplot shown for the stimulation of DG75-COex at 25 μg in the presence of IL-21 was inadvertently duplicated from the 5 μg/IL-21 panel. The indicated frequency of 5% of CD38highCD20low B cells, however, is correct. This correct value of 5% was used in Fig. 6B, so the error in Fig. 6A did not influence the interpretation of the results and conclusions of this work. Fig. 6A has now been corrected with the correct dotplot for stimulation of DG75-COex at 25 μg in the presence of IL-21. The corrected version of Fig. 6 is shown below. The figure legend was correct as published and is shown below for reference. Fig. 6 has also been corrected in the online ...
Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis.Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis.
The p53 tumor suppressor pathway limits oncogenesis by inducing cell cycle arrest or apoptosis. A key p53 target gene is PUMA, which encodes a BH3-only proapoptotic protein. Here we demonstrate that Puma deletion in the Emu-Myc mouse model of Burkitt lymphoma accelerates lymphomagenesis and that approximately 75% of Emu-Myc lymphomas naturally select against Puma protein expression. Furthermore, approximately 40% of primary human Burkitt lymphomas fail to express detectable levels of PUMA and in some tumors this is associated with DNA methylation. Burkitt lymphoma cell lines phenocopy the primary tumors with respect to DNA methylation and diminished PUMA expression, which can be reactivated following inhibition of DNA methyltransferases. These findings establish that PUMA is silenced in human malignancies, and they suggest PUMA as a target for the development of novel chemotherapeutics.. ...
Burkitt lymphoma facts, information, pictures | Encyclopedia.com articles about Burkitt lymphomaBurkitt lymphoma facts, information, pictures | Encyclopedia.com articles about Burkitt lymphoma
Get information, facts, and pictures about Burkitt lymphoma at Encyclopedia.com. Make research projects and school reports about Burkitt lymphoma easy with credible articles from our FREE, online encyclopedia and dictionary.
CyFlowâ„¢ CD29 Purified | Expanded Antibody Search | Antibodies | Reagents | Sysmex Flow Cytometry EuropeCyFlowâ„¢ CD29 Purified | Expanded Antibody Search | Antibodies | Reagents | Sysmex Flow Cytometry Europe
HLDA WorkshopHLDA VI-WS Code AS A048 Concentration Unitmg/mLConcentration1Quantity0.1 mgVolume0.1ImmunogenRaji cells: human Burkitts lymphoma cell...
Cancers | Free Full-Text | The miR-26b-5p/KPNA2 Axis Is an Important Regulator of Burkitt Lymphoma Cell GrowthCancers | Free Full-Text | The miR-26b-5p/KPNA2 Axis Is an Important Regulator of Burkitt Lymphoma Cell Growth
The expression of several microRNAs (miRNAs) is known to be changed in Burkitt lymphoma (BL), compared to its normal counterparts. Although for some miRNAs, a role in BL was demonstrated, for most of them, their function is unclear. In this study, we aimed to identify miRNAs that control BL cell growth. Two BL cell lines were infected with lentiviral pools containing either 58 miRNA inhibitors or 44 miRNA overexpression constructs. Eighteen constructs showed significant changes in abundance over time, indicating that they affected BL growth. The screening results were validated by individual green fluorescent protein (GFP) growth competition assays for fifteen of the eighteen constructs. For functional follow-up studies, we focused on miR-26b-5p, whose overexpression inhibited BL cell growth. Argonaute 2 RNA immunoprecipitation (Ago2-IP) in two BL cell lines revealed 47 potential target genes of miR-26b-5p. Overlapping the list of putative targets with genes showing a growth repression phenotype in a
Burkitts tumor synonyms, Burkitts tumor antonyms - FreeThesaurus.comBurkitt's tumor synonyms, Burkitt's tumor antonyms - FreeThesaurus.com
Synonyms for Burkitt's tumor in Free Thesaurus. Antonyms for Burkitt's tumor. 2 synonyms for tumor: neoplasm, tumour. What are synonyms for Burkitt's tumor?
Burkitt - WikipediaBurkitt - Wikipedia
Burkitt is an ancient name of Anglo-Saxon origin, and may refer to: Denis Parsons Burkitt, surgeon Francis Crawford Burkitt, British theologian Jack Burkitt, English footballer James Parsons Burkitt, ornithologist M. C. Burkitt, British palaeohistorian William Burkitt, biblical expositor and vicar in Dedham, Essex, England Judge Sir William Burkitt Burkitts lymphoma Burkitt name origin Alternative origin of Burkitt ...
Role of the p53 Tumor Suppressor Gene in the Tumorigenicity of Burkitts Lymphoma Cells | Cancer ResearchRole of the p53 Tumor Suppressor Gene in the Tumorigenicity of Burkitt's Lymphoma Cells | Cancer Research
Burkitts lymphoma (BL) cell lines carry a translocated c-myc gene and, in 60-80% of cases, exhibit mutations in the p53 tumor suppressor gene. We examined the potential role of the p53 gene in BL tumorigenicity using an in vitro assay that measures p53-dependent cell cycle arrest in the G1 phase of the cell cycle and an in vivo athymic murine model that detects differences in the tumorigenicity of BL cell lines. A highly significant inverse correlation was found between the ability of BL cells to arrest in G1 after irradiation and their tumorigenicity in athymic mice, consistent with the notion that loss of p53 function is associated with increased tumorigenicity. Inactivation of wild-type (wt) p53 function by expression of the human papillomavirus E6 protein in the AG876V BL cell line, which carries both wt and mutant p53 proteins, rendered the cell line significantly more tumorigenic in athymic mice. Transfection of the wt p53 gene into the p53 mutant and highly tumorigenic BL-41 cell line ...
CyFlowâ„¢ CD19 PE-Cy7 | Expanded Antibody Search | Antibodies | Reagents | Sysmex Belgium Flow CytometryCyFlowâ„¢ CD19 PE-Cy7 | Expanded Antibody Search | Antibodies | Reagents | Sysmex Belgium Flow Cytometry
HLDA WorkshopHLDA 10Quantity100 testsVolume0.4ImmunogenDaudi human Burkitt lymphoma cell lineBackground InformationCD19 is a transmembrane glycopro...
CyFlowâ„¢ CD19 PE | Expanded Antibody Search | Reagents | Sysmex Flow Cytometry CanadaCyFlowâ„¢ CD19 PE | Expanded Antibody Search | Reagents | Sysmex Flow Cytometry Canada
HLDA WorkshopHCDM/HLDA 10Quantity100 testsVolume2.0 mLImmunogenDaudi human Burkitt lymphoma cell lineBackground InformationCD19 is a transmembrane gl…
CyFlowâ„¢ CD19 APC | Expanded Antibody Search | Reagents | Sysmex Flow Cytometry CanadaCyFlowâ„¢ CD19 APC | Expanded Antibody Search | Reagents | Sysmex Flow Cytometry Canada
HLDA WorkshopHCDM/HLDA 10Quantity100 testsVolume1.0 mLImmunogenDaudi human Burkitt lymphoma cell lineBackground InformationCD19 is a transmembrane gl…
Prestren | Burkitts lymphoma - PrestrenPrestren | Burkitt's lymphoma - Prestren
Burkitts lymphoma is a sort of aggressive B-cell lymphoma. This condition is most usually observed in youngsters and isolated into three types:. - Endemic - this is generally seen in children living in Africa. Usually, this kind of Burkitts lymphoma affects the facial bones such as the jaw, the intestines such as the distal ileum and cecum. Other stomach parts such as the ovaries and kidneys can also be affected.. - Sporadic/Non-African - found outside of Africa and affects the same parts as that of the endemic mixed bag.. - Immunodeficiency associated - this kind of Burkitts lymphoma is usually seen in HIV patients or patients taking insusceptible suppressive drugs.. Causes. Alongside the stated associated factors, Burkitts lymphoma is exceptionally joined with Epstein-Barr virus and jungle fever. The virus creates a change inside the B-cells, a kind of lymphocyte found in the safe system. Exposure to jungle fever weakens the cells resistance to the virus effects, making it one of the ...
Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes<...Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes<...
TY - JOUR. T1 - Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. AU - Piccaluga, Pier Paolo. AU - De Falco, Giulia. AU - Kustagi, Manjunath. AU - Gazzola, Anna. AU - Agostinelli, Claudio. AU - Tripodo, Claudio. AU - Leucci, Eleonora. AU - Onnis, Anna. AU - Astolfi, Annalisa. AU - Sapienza, Maria Rosaria. AU - Bellan, Cristiana. AU - Lazzi, Stefano. AU - Tumwine, Lynnette. AU - Mawanda, Michael. AU - Ogwang, Martin. AU - Calbi, Valeria. AU - Formica, Serena. AU - Califano, Andrea. AU - Pileri, Stefano A.. AU - Leoncini, Lorenzo. PY - 2011/3/31. Y1 - 2011/3/31. N2 - Burkitt lymphoma (BL) is classified into 3 clinical subsets: endemic, sporadic, and immunodeficiency-associated BL. So far, possible differences in their gene expression profiles (GEPs) have not been investigated. We studied GEPs of BL subtypes, other B-cell lymphomas, and B lymphocytes; first, we found that BL is a unique molecular entity, distinct from other B-cell malignancies. Indeed, by ...
glossary:burkitt s lymphomaglossary:burkitt s lymphoma
Burkitts Lymphoma n. (Medicine / Pathology) a rare type of tumour of the white blood cells, occurring mainly in Africa and associated with infection by Epstein-Barr virus. From MedTerms: A type of non-Hodgkin lymphoma (NHL) that most often occurs in young people between the ages of 12 and 30, accounting for 40% to 50% of childhood NHL. The disease usually causes a rapidly growing tumor in the abdomen. Up to 90% of these tumors are in the abdomen. Other sites of involvement include the testis, sinuses, bone, lymph nodes, skin, bone marrow, and central nervous system. Burkitt lymphoma is a small noncleaved cell lymphoma of B-cell origin. About 25% of Burkitt lymphomas contain Epstein-Barr virus genomes. Burkitt lymphoma is due to a characteristic chromosomal translocation, usually a t(8;14) translocation or, less often, a t(8;22) or t(2;8) translocation. Each of these translocations juxtaposes the c-myc oncogene with immunoglobulin locus regulatory elements, resulting in the inappropriate ...
glossary:burkitt s lymphomaglossary:burkitt s lymphoma
Burkitts Lymphoma n. (Medicine / Pathology) a rare type of tumour of the white blood cells, occurring mainly in Africa and associated with infection by Epstein-Barr virus. From MedTerms: A type of non-Hodgkin lymphoma (NHL) that most often occurs in young people between the ages of 12 and 30, accounting for 40% to 50% of childhood NHL. The disease usually causes a rapidly growing tumor in the abdomen. Up to 90% of these tumors are in the abdomen. Other sites of involvement include the testis, sinuses, bone, lymph nodes, skin, bone marrow, and central nervous system. Burkitt lymphoma is a small noncleaved cell lymphoma of B-cell origin. About 25% of Burkitt lymphomas contain Epstein-Barr virus genomes. Burkitt lymphoma is due to a characteristic chromosomal translocation, usually a t(8;14) translocation or, less often, a t(8;22) or t(2;8) translocation. Each of these translocations juxtaposes the c-myc oncogene with immunoglobulin locus regulatory elements, resulting in the inappropriate ...
Burkitt lymphoma : epidemiological features and survival in a South African centreBurkitt lymphoma : epidemiological features and survival in a South African centre
Background: The epidemiology of Burkitt Lymphoma (BL) shows that the endemic type is mainly confined to equatorial Africa and has a very close association with the Epstein-Barr virus (EBV), while the sporadic variant shows only a 20% association with EBV and is seen mainly in Europe and North America. An immunodeficent form of BL has been described more recently. This study aimed to describe the epidemiological characteristics and survival of children presenting with BL to Tygerberg Hospital, Cape Town, in South Africa. Methods: A retrospective, descriptive study reviewed all pediatric cases of Burkitt lymphoma at Tygerberg Hospital Oncology Unit between 1 January 1995 and 31 December 2010. The following data were analysed: age at diagnosis, gender, anatomic site, race, socio-economic demographic (rural vs. urban), treatment protocol, side effects, viral characteristics and survival. All cases were confirmed by histology and reviewed by a tumour board. Results: A total of 51 patients with ...
Long term survival of children with burkitt lymphoma in Malawi after cyclophosphamide monotherapyLong term survival of children with burkitt lymphoma in Malawi after cyclophosphamide monotherapy
Background. Between 1991 and 1997, limited funding at times restricted available treatment for children with Burkitt lymphoma (BL) to cyclophosphamide (CPM) monotherapy at Lilongwe Central Hospital, Malawi. Our objective was to assess long-term survival in Malawian children with Burkitt lymphoma (BL) who had received one or more treatments with intravenous CPM at 40 mg/kg/dose at 14-day intervals. Procedure and Results. The study population consisted of 92 children in whom BL had been confirmed on fine needle aspirates (FNA), a home address had been documented on discharge from hospital, and the treatment records could be verified. Only the clinical site(s) of disease had been recorded. The M:F ratio was 1.4 and median age 8 years. A clinical officer on motorcycle attempted to locate the given addresses and interview parents or other sources. In 19 patients, the address was incorrect. Of 73 evaluable patients, 40 children are alive at a mean follow-up time of 59 (range: 29-104) months. The ...
Adult Burkitt Lymphoma: An Unusual Presentation | International Journal Of PathologyAdult Burkitt Lymphoma: An Unusual Presentation | International Journal Of Pathology
Shahzad Ali Jiskani, Asfa Zawar and Lubna Naseem. Department of Pathology, Pakistan Institute of Medical Sciences, Islamabad. Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad. Abstract: Burkitt lymphoma is a disease of young population; especially children. It rarely occurs and presented in elderly group. World Heal Organization (WHO) divided Burkitt lymphoma in endemic, sporadic and immunodeficiency - associated. The non - endemic variant occur in children with abdominal involvement. We report a sporadic case presented at the age of 61 years old male with irregular thickening or parietal peritoneum and omentum without involving any lymph nodes. ...
Reports on Cure 250 Children with Burkitt Lymphoma in Africa - GlobalGivingReports on Cure 250 Children with Burkitt Lymphoma in Africa - GlobalGiving
Ruth was 9 years old when she first came to St Marys Hospital Lacor in Gulu. She is from a village in Lira, the district that borders Gulu in northern Uganda. Her father brought her to St Marys in June 2019 after she experienced a one-month history of progressive and painful abdominal swelling. When she was admitted to our hospital, Ruth was quite ill. Her nutritional status was very poor and she had severe wasting. Upon examination, she had a grossly distended abdomen and an ill-defined mass that was palpable and very large. She underwent blood work, a chest x-ray and an ultrasound of her abdomen. The ultrasound revealed that she had multiple tumors in her liver, a separate large mass within her abdominal cavity as well as fluid in the abdomen. A biopsy of the large abdominal mass was performed which confirmed that she had Burkitt lymphoma.. Ruth required supportive care, including nutritional support, and was started on first-line (FL) chemotherapy for Burkitt lymphoma that consisted of ...
Plus itPlus it
Indeed, infection by Helicobacter pylori (H. pylori) has been recognized as a critical driver of mucosa-associated lymphoid tissue B-cell lymphoma, which is often reversible by antibiotic therapy. Likewise, chronic B-cell activation in the context of hepatitis C virus (HCV) infection was identified as a causative agent in the etiology of HCV-associated diffuse large B-cell lymphomas. Key evidence for this concept comes from a recent study on the role of Plasmodium falciparum (P. falciparum) in the etiology of endemic Burkitt lymphoma (5). In a genetic mouse model for chronic recurrent malaria infection, this study demonstrated that chronic B-cell activation in this model causes aberrant activation of AID and AID-mediated genomic instability leading to B-cell lymphoma. Of note, development of B-cell lymphoma in this model was critically dependent on protracted AID activity (somatic hypermutation and class-switch recombination) in the presence of plasmodium infection.. Initial genetic lesions ...
Mechanism of cell death in Burkitt lymphomasMechanism of cell death in Burkitt lymphomas
Apoptosis resistance is the major cause of chemotherapy failure in most kinds of cancers, including Burkitt lymphomas (BL). To elucidate molecular mechanisms regulating the development of apoptosis resistance, a panel of 15 BL cell lines was investigated for apoptosis induction upon treatment with microtubule inhibitors taxol, nocodazole and vincristine. Significant differences were observed in the extent of apoptosis induction among BL cell lines examined. Interestingly, cell lines exhibiting resistance to taxol- or nocodazole-induced apoptosis, showed development of polyploidy (,4N) and vice versa, displaying an inverse relationship between apoptosis and polyploidy induction. Further, in sensitive cell lines taxol-induced apoptosis was accompanied by caspase activation, Bid cleavage and Mcl-1 down-regulation. In contrast, most apoptosis resistant cell lines exhibited a loss of Bax and Bak expression and showed prolonged mitotic arrest with ,4N DNA content upon treatment. To gain mechanistic ...
Transcription enhancer identified near the human C mu immunoglobulin heavy chain gene is unavailable to the translocated c-myc...Transcription enhancer identified near the human C mu immunoglobulin heavy chain gene is unavailable to the translocated c-myc...
In Burkitt lymphoma the c-myc gene, the cellular homologue of the viral oncogene v-myc, has been implicated in the aetiology of this human B-cell malignancy. Burkitt lymphoma cells possess specific chromosomal rearrangements involving the region proximal to the c-myc gene and one of the three human immunoglobulin loci. The nature of the effect exerted by the immunoglobulin loci on the translocated c-myc gene is controversial: whereas some reports have suggested c-myc transcription is elevated in Burkitt lymphoma cells, others have suggested the level of transcription is unaffected by the translation. Recently, transcription enhancer elements have been identified in the intron between the JH and C mu segments of the heavy-chain immunoglobulin gene in mice. If similar enhancers exist in humans they may lead to increased transcription of the translocated c-myc gene and thus contribute to oncogenesis in Burkitt lymphoma. We report here the identification of an enhancer element adjacent to the human C mu
Epstein-Barr virus provides a survival factor to Burkitts lymphomas. - Semantic ScholarEpstein-Barr virus provides a survival factor to Burkitt's lymphomas. - Semantic Scholar
Epstein-Barr virus (EBV) has been causally associated with at least five human malignancies. The exact contributions made by EBV to these cancers remain unknown. We demonstrate that one viral protein found in all EBV-associated malignancies, Epstein-Barr nuclear antigen 1 (EBNA-1), is required for survival of one of these cancers, EBV-positive Burkitts lymphoma. Inhibition of EBNA-1 decreases survival of these tumor cells by inducing apoptosis. Expression of EBNA-1 in uninfected cells also can inhibit apoptosis induced by expression of p53 in the absence of the EBV genome. Our findings demonstrate that EBNA-1 is critical for the continued survival of EBV-associated Burkitts lymphoma, and, by extension, for the other B cell tumors with which EBV is associated. Efficient inhibitors of EBNA-1s functions would likely prove useful in the therapy of EBV-associated malignancies.
Staff Profile - Northern Institute for Cancer Research - Newcastle UniversityStaff Profile - Northern Institute for Cancer Research - Newcastle University
Zhou P, Newman AM, Van Noorden S, Banda K, Chagaluka G, Lampert I, Erhorn A, Bacon C, Bailey S, Molyneux E, Rand V. Investigation of prognostic markers in endemic Burkitt lymphoma. In: Fifth International Symposium on Childhood Adolescent and Young Adult Non-Hodgkin Lymphoma. 2015, Varese, Italy: Wiley-Blackwell Publishing Ltd ...
MINCR is a MYC-induced lncRNA able to modulate MYCs transcriptional network in Burkitt lymphoma cells - KielprintsMINCR is a MYC-induced lncRNA able to modulate MYC's transcriptional network in Burkitt lymphoma cells - Kielprints
Despite the established role of the transcription factor MYC in cancer, little is known about the impact of a new class of transcriptional regulators, the long noncoding RNAs (lncRNAs), on MYC ability to influence the cellular transcriptome. Here, we have intersected RNA-sequencing data from two MYC-inducible cell lines and a cohort of 91 B-cell lymphomas with or without genetic variants resulting in MYC overexpression. We identified 13 lncRNAs differentially expressed in IG-MYC-positive Burkitt lymphoma and regulated in the same direction by MYC in the model cell lines. Among them, we focused on a lncRNA that we named MYC-induced long noncoding RNA (MINCR), showing a strong correlation with MYC expression in MYC-positive lymphomas. To understand its cellular role, we performed RNAi and found that MINCR knockdown is associated with an impairment in cell cycle progression. Differential gene expression analysis after RNAi showed a significant enrichment of cell cycle genes among the genes ...
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.
The c-Myc oncoprotein promotes proliferation and apoptosis, such that mutations that disable apoptotic programmes often cooperate with MYC during tumorigenesis. Here we report that two common mutant MYC alleles derived from human Burkitts lymphoma uncouple proliferation from apoptosis and, as a result, are more effective than wild-type MYC at promoting B cell lymphomagenesis in mice. Mutant MYC proteins retain their ability to stimulate proliferation and activate p53, but are defective at promoting apoptosis due to a failure to induce the BH3-only protein Bim (a member of the B cell lymphoma 2 (Bcl2) family) and effectively inhibit Bcl2. Disruption of apoptosis through enforced expression of Bcl2, or loss of either Bim or p53 function, enables wild-type MYC to produce lymphomas as efficiently as mutant MYC. These data show how parallel apoptotic pathways act together to suppress MYC-induced transformation, and how mutant MYC proteins, by selectively disabling a p53-independent pathway, enable ...
A carbohydrate-binding protein with a SUEL-type lectin domain promotes investigation of minimally invasive therapy by the...A carbohydrate-binding protein with a SUEL-type lectin domain promotes investigation of minimally invasive therapy by the...
SAL is a Gb3 (Galα1-4Galβ1-4Glc)-binding lectin with three SUEL-type lectin domains which was purified from catfish eggs. The lectin depleted expression of mRNA coding multidrug resistant protein, MRP1, time- and dose-dependently through binding with Gb3 glycosphingolipid which is highly expressed on human Burkitts lymphoma Raji cells. This interaction inhibited the excretion of chemotherapy drugs. The administration of vincristine could effectively killed Raji cells even at l/10 lower concentration than the lethal-doses, if co-treatment with SAL was conducted. The Japanese Association for Marine Biology (JAMBIO) in MEXT Japan identified this research as a leading edge topic as part of their 2012 research activities reporting. These results were possible through the work of Assist. Profs. Yuki Fujii (Nagasaki International University and adjunct researcher of Yokonama City University) and Shigeki Sugawara (Tohoku Pharmaceutical University), Assoc. Prof. Sarkar M. Abe Kawsar (University of ...
Which pro-survival BCL-2 family member should be targeted for the treatment of which cancer? - NCRI Cancer Conference abstractsWhich pro-survival BCL-2 family member should be targeted for the treatment of which cancer? - NCRI Cancer Conference abstracts
Impaired apoptosis is considered a prerequisite for the development of most, if not all, cancers, but the mechanisms that guarantee sustained survival of most cancer cells remain unknown. Members of the BCL-2 family of proteins are key regulators of apoptosis and include proteins essential for cell survival and those required to initiate cell death. Studies with transgenic mice have shown that over-expression of BCL-2 or related pro-survival family proteins, such as BCL-XL or MCL-1, can promote tumorigenesis, particularly in conjunction with mutations that deregulate cell cycle control, such as deregulated c-MYC expression. It is, however, not known whether expression of pro-survival BCL-2 family members under endogenous control is required to maintain survival of cells undergoing neoplastic transformation. Using Eµ-Myc transgenic mice, a well-characterized model of human Burkitts lymphoma, and other murine cancer models, we investigated the role of BCL-2 pro-survival proteins when expressed ...
Inhibition of Epstein-Barr virus (EBV) release from the P3HR-1 Burkitts lymphoma cell line by a monoclonal antibody against a...Inhibition of Epstein-Barr virus (EBV) release from the P3HR-1 Burkitt's lymphoma cell line by a monoclonal antibody against a...
In raising murine hybridoma antibodies against Epstein-Barr virus (EBV)-induced membrane antigens (MA), we found one antibody that blocked the release of infectious EBV from cultured P3HR-1 cells. This monoclonal antibody (mAb) recognized a 200 kD, phosphonoacetic acid-sensitive (late) MA, and did not directly neutralize virus without complement. When this mAb was added to 33 degrees C-cultured, spontaneously EBV-producing P3HR-1 cells, the intracellular expression of viral capsid antigen and infectious virus was not inhibited, but the appearance of infectious virus in the culture medium was significantly reduced. The duration of this suppression was dependent upon the concentration of the mAb, an effect being observed to a 1:4 X 10(5) titer of the ascites mAb preparation. A more acute effect of suppression of EBV release was observed in a second model of 12-o-tetradecanoyl phorbol-13-acetate and n-butyrate induction of EBV in 37 degrees C-cultured P3HR-1 cells. Again, intracellular infectious ...
Targeting Burkitt Lymphoma with a Tumor Cell-specific Heptamethine Carbocyanine-cisplatin Conjugate | Repository UHC OsijekTargeting Burkitt Lymphoma with a Tumor Cell-specific Heptamethine Carbocyanine-cisplatin Conjugate | Repository UHC Osijek
BACKGROUND: Burkitt lymphoma is a fast-growing mature B cell malignancy, whose genetic hallmark is translocation and activation of the c-myc gene. Prompt multiagent immunochemotherapy regimens can have favorable outcomes, but prognosis is poor in refractory or relapsed disease. We previously identified a novel family of near-infrared heptamethine carbocyanine fluorescent dyes (HMCD or DZ) with tumor-homing properties via organic anion-transporting peptides. These membrane carriers have uptake in tumor cells but not normal cells in cell culture, mouse and dog tumor models, patient-derived xenografts, and perfused kidney cancers in human patients. METHODS: Here we report the cytotoxic effects of a synthesized conjugate of DZ with cisplatin (CIS) on B cell lymphoma CA46, Daudi, Namalwa, Raji, and Ramos cell lines in cell culture and in xenograft tumor formation. Impaired mitochondrial membrane permeability was examined as the mechanism of DZ-CIS-induced lymphoma cell death. RESULTS: The new ...
Burkitts Lymphoma - beck-shop.deBurkitt's Lymphoma - beck-shop.de
The study of Burkitts lymphoma is now in its 6 decade beginning with its discovery by Dr. Dennis Burkitt in equatorial Africa in the mid to late 1950s. A large body of information is available which provides a current understanding of the underlying molecular changes that are linked to the initiation and development of Burkitts lymphoma. This proposed volume will provide a comprehensive view of Burkitts Lymphoma from the diagnosis to potential animal models for this disease and include a view from physicians who have a up close view of the patients in populations where the disease is rampant. We expect that this will be an excellent resource for Medical students and faculty as well as educated laypersons who have a person interest in the disease ...
Burkitts lymphoma - WikipediaBurkitt's lymphoma - Wikipedia
Burkitt lymphoma is a cancer of the lymphatic system, particularly B lymphocytes found in the germinal center. It is named after Denis Parsons Burkitt, a surgeon who first described the disease in 1958 while working in equatorial Africa. Currently, Burkitt lymphoma can be divided into three main clinical variants: the endemic, the sporadic, and the immunodeficiency-associated variants. The endemic variant (also called "African variant") most commonly occurs in children living in malaria endemic regions of the world (e.g., equatorial Africa, Brazil, and Papua New Guinea). Epstein-Barr virus (EBV) infection is found in nearly all patients. Chronic malaria is believed to reduce resistance to EBV, allowing it to take hold. The disease characteristically involves the jaw or other facial bone, distal ileum, cecum, ovaries, kidney, or breast. The sporadic type of Burkitt lymphoma (also known as "non-African") is the most common variant found in places where malaria is not holoendemic. The tumor cells ...
penanganan burkitt lymphomapenanganan burkitt lymphoma
Burkitt Lymphoma atau Limfoma Burkitt adalah bentuk limfoma non-Hodgkin di mana kanker mulai tumbuh pada sel darah putih yang disebut. Baca Selengkapnya ...
Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the...Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the...
Burkitt lymphoma (BL) has a characteristic clinical presentation, morphology, immunophenotype and primary chromosomal aberration, that is, the translocation t(8;14)(q24;q32) or its variants. However, diagnostic dilemmas may arise in daily practice due to overlap of BL with subsets of other aggressive, mature B-cell lymphomas such as diffuse large B-cell lymphomas (DLBCL). Recently, two gene expression studies have described a distinct molecular profile for BL, but also showed the persistence of some cases intermediate between BL and DLBCL. An alternative approach to define BL is to consider (cyto)genetic data, in particular chromosomal abnormalities other than the t(8;14) or its variants. In this review the Mitelman Database of Chromosome Aberrations in Cancer, harboring the majority of all published neoplasia-related karyotypes, was explored to define a cytogenetic profile of true BL. This core subset of BL showed a very low complexity of chromosomal abnormalities with 40% of the cases ...
Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitts lymphoma cell lines. - PubMed - NCBIOngoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt's lymphoma cell lines. - PubMed - NCBI
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell...Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell...
Burkitt lymphoma/leukemia (BL) is highly treatable, but most of the standard therapies require multiple doses of intensive chemotherapy that may require long hospital stays and frequently have severe side effects. In addition, BL is a fairly common type of cancer in patients who also have human immunodeficiency virus (HIV), but treatment outcomes are poor because standard treatments do not work very well in HIV-positive patients and the more intense treatment regimens are highly toxic. New approaches are needed that expand the ways to treat BL with the same efficiency but with reduced side effects ...
Epstein-Barr virus infectionEpstein-Barr virus infection
List of OMIM disorder codesList of OMIM disorder codes
Bozoma Saint JohnBozoma Saint John
Alexander John HaddowAlexander John Haddow
Azzopardi phenomenonAzzopardi phenomenon
Raji cellRaji cell
Epstein-Barr virus stable intronic-sequence RNAsEpstein-Barr virus stable intronic-sequence RNAs
Bert AchongBert Achong
QSER1QSER1
OncovirusOncovirus
Epstein-Barr virusEpstein-Barr virus
Idiopathic CD4+ lymphocytopeniaIdiopathic CD4+ lymphocytopenia
History of virologyHistory of virology
Michael A. EpsteinMichael A. Epstein
1964 in science1964 in science
Sid CoucheySid Couchey
MycMyc
MiR-155MiR-155
UWA-101UWA-101
DNADNA
LymphocryptovirusLymphocryptovirus
DNA-binding proteinDNA-binding protein
Chorioallantoic membraneChorioallantoic membrane
Eva KleinEva Klein
FCRL5FCRL5
Ronald LevyRonald Levy
HLA-A11HLA-A11
Mir-16 microRNA precursor familyMir-16 microRNA precursor family
UWA-001UWA-001
CXCR5CXCR5
AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaInformation ScienceHealth Care
Burkitt LymphomaLymphomaLymphoma, B-CellLymphoma, Non-HodgkinLymphoma, Large B-Cell, DiffuseLymphoma, T-CellHerpesvirus 4, HumanLymphoma, FollicularLymphoma, AIDS-RelatedTranslocation, GeneticChromosomes, Human, 6-12 and XLymphoma, B-Cell, Marginal ZoneEpstein-Barr Virus Nuclear AntigensChromosomes, Human, 13-15Glutamate FormimidoyltransferaseGenes, mycProto-Oncogene Proteins c-mycB-LymphocytesEpstein-Barr Virus InfectionsLymphoma, Mantle-CellLymphoma, T-Cell, CutaneousHodgkin DiseaseLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, AnaplasticChromosomes, Human, Pair 14VincristineTumor Cells, CulturedGerminal CenterOncogenesAntibodies, Monoclonal, Murine-DerivedCyclophosphamideIn Situ Hybridization, FluorescenceAntigens, CD20Chromosomes, Human, 1-3Genes, Immunoglobulin Heavy ChainCell Line, TumorImmunophenotypingImmunoglobulin Heavy ChainsCell LineSesquiterpenes, GuaianeLeukemia, B-CellDoxorubicinGene RearrangementSesquiterpenes, EudesmaneChromosomes, Human, Pair 8NeprilysinCytogeneticsAntineoplastic Combined Chemotherapy ProtocolsLymphoma, Large-Cell, ImmunoblasticViral Matrix ProteinsHLA-A11 AntigenGenes, mybImmunohistochemistryGene Expression Regulation, NeoplasticProto-Oncogene Proteins c-bcl-2Genes, bcl-2PlasmacytomaCytarabineBase SequenceApoptosisAntibodies, MonoclonalTanacetum partheniumFlow CytometryVirus LatencyAntigens, ViralPrednisoneInhibitor of Differentiation ProteinsLymphoproliferative DisordersDNA, NeoplasmGenes, ImmunoglobulinChromosome BandingKaryotypingTreatment OutcomeMethotrexateReceptors, Antigen, B-CellCell Transformation, ViralNeoplasm ProteinsAntineoplastic AgentsEtoposideMolecular Sequence DataProto-OncogenesLeukemia, LymphoidPrognosisLymphocytesRemission InductionLymphoma, Extranodal NK-T-CellCell Transformation, NeoplasticTumor Markers, BiologicalTranscription, GeneticCell Line, TransformedPolymerase Chain ReactionGene Expression Regulation, ViralDNA, ViralChaperonin Containing TCP-1BiopsyHybrid CellsVirus ActivationNational Cancer Institute (U.S.)
Burkitts lymphoma - WikipediaBurkitt's lymphoma - Wikipedia
Burkitts Lymphoma | Definition of Burkitts Lymphoma by Merriam-WebsterBurkitt's Lymphoma | Definition of Burkitt's Lymphoma by Merriam-Webster
Burkitt lymphoma facts, information, pictures | Encyclopedia.com articles about Burkitt lymphomaBurkitt lymphoma facts, information, pictures | Encyclopedia.com articles about Burkitt lymphoma
Burkitts lymphomasBurkitt's lymphomas
Mechanism of cell death in Burkitt lymphomasMechanism of cell death in Burkitt lymphomas
Burkitt Lymphoma and Burkitt-like Lymphoma: Practice Essentials, Background, Etiology and PathophysiologyBurkitt Lymphoma and Burkitt-like Lymphoma: Practice Essentials, Background, Etiology and Pathophysiology
Medical Xpress - burkitt lymphomaMedical Xpress - burkitt lymphoma
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma - Tabular View - ClinicalTrials.govIntensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma - Tabular View - ClinicalTrials.gov
Burkitts lymphoma: a childs case presenting in the maxilla. Clinical and radiological aspects.Burkitt's lymphoma: a child's case presenting in the maxilla. Clinical and radiological aspects.
Reports on Cure 250 Children with Burkitt Lymphoma in Africa - GlobalGivingReports on Cure 250 Children with Burkitt Lymphoma in Africa - GlobalGiving
Cancers | Free Full-Text | The miR-26b-5p/KPNA2 Axis Is an Important Regulator of Burkitt Lymphoma Cell GrowthCancers | Free Full-Text | The miR-26b-5p/KPNA2 Axis Is an Important Regulator of Burkitt Lymphoma Cell Growth
5 Home Remedies For Burkitt Lymphoma - Natural Home Remedies & Supplements5 Home Remedies For Burkitt Lymphoma - Natural Home Remedies & Supplements
Deregulation of DNMT1, DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution for disease pathogenesis. | Sigma...Deregulation of DNMT1, DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution for disease pathogenesis. | Sigma...
Role of the p53 Tumor Suppressor Gene in the Tumorigenicity of Burkitts Lymphoma Cells | Cancer ResearchRole of the p53 Tumor Suppressor Gene in the Tumorigenicity of Burkitt's Lymphoma Cells | Cancer Research
Correction: Exosomes Derived from Burkitts Lymphoma Cell Lines Induce Proliferation, Differentiation, and Class-Switch...Correction: Exosomes Derived from Burkitt's Lymphoma Cell Lines Induce Proliferation, Differentiation, and Class-Switch...
Inhibition of Epstein-Barr virus (EBV) release from the P3HR-1 Burkitts lymphoma cell line by a monoclonal antibody against a...Inhibition of Epstein-Barr virus (EBV) release from the P3HR-1 Burkitt's lymphoma cell line by a monoclonal antibody against a...
Burkitts lymphoma - WikipediaBurkitt's lymphoma - Wikipedia
What is Burkitt lymphoma?What is Burkitt lymphoma?
How is Burkitt lymphoma diagnosed?How is Burkitt lymphoma diagnosed?
Histology of Burkitts lymphoma. | The BMJHistology of Burkitt's lymphoma. | The BMJ
Epidemiologic Notes and Reports Burkitts Lymphoma -- Winchester, VirginiaEpidemiologic Notes and Reports Burkitt's Lymphoma -- Winchester, Virginia
Burkitt lymphoma - Canadian Cancer SocietyBurkitt lymphoma - Canadian Cancer Society
Survival Rates for Childhood Non-Hodgkin & Burkitt LymphomaSurvival Rates for Childhood Non-Hodgkin & Burkitt Lymphoma
Orbital Burkitts Lymphoma: An Aggressive PresentationOrbital Burkitt's Lymphoma: An Aggressive Presentation
Treatments for childhood Burkitt lymphoma - Canadian Cancer SocietyTreatments for childhood Burkitt lymphoma - Canadian Cancer Society
Primary Breast Burkitts Lymphoma in an HIV-Infected WomanPrimary Breast Burkitt's Lymphoma in an HIV-Infected Woman
Burkitts lymphoma dictionary definition | Burkitts lymphoma definedBurkitt's lymphoma dictionary definition | Burkitt's lymphoma defined
Microgeographic variations in Burkitts lymphomaMicrogeographic variations in Burkitt's lymphoma
Infectious Disease: Lymphoreticular: Burkitt Lymphoma | Podcasts | Naked ScientistsInfectious Disease: Lymphoreticular: Burkitt Lymphoma | Podcasts | Naked Scientists
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. - PubMed - NCBIBurkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. - PubMed - NCBI
Burkitt Lymphoma | Alexs Lemonade Stand Foundation for Childhood CancerBurkitt Lymphoma | Alex's Lemonade Stand Foundation for Childhood Cancer
PRIME PubMed | Burkitts lymphoma: clinicopathologic features and differential diagnosiPRIME PubMed | Burkitt's lymphoma: clinicopathologic features and differential diagnosi
Definition of Burkitt lymphoma - NCI Dictionary of Cancer Terms - National Cancer InstituteDefinition of Burkitt lymphoma - NCI Dictionary of Cancer Terms - National Cancer Institute
Burkitts lymphoma of the colonBurkitt's lymphoma of the colon
A glycolipid antigen associated with Burkitt lymphoma defined by a monoclonal antibody | ScienceA glycolipid antigen associated with Burkitt lymphoma defined by a monoclonal antibody | Science
Burkitts lymphoma with bilateral cavernous sinus and mediastinal involvement in a child | SpringerLinkBurkitt's lymphoma with bilateral cavernous sinus and mediastinal involvement in a child | SpringerLink
Article - Burkitt lymphoma causing colocolonic intussusceptionArticle - Burkitt lymphoma causing colocolonic intussusception
Burkitt lymphoma - Renal and Urology NewsBurkitt lymphoma - Renal and Urology News
Lymphoma (Burkitt, Hodgkin, and non-Hodgkin) - National Cancer InstituteLymphoma (Burkitt, Hodgkin, and non-Hodgkin) - National Cancer Institute
AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaInformation ScienceHealth Care
Burkitt LymphomaLymphomaLymphoma, B-CellLymphoma, Non-HodgkinLymphoma, Large B-Cell, DiffuseLymphoma, T-CellHerpesvirus 4, HumanLymphoma, FollicularLymphoma, AIDS-RelatedTranslocation, GeneticChromosomes, Human, 6-12 and XLymphoma, B-Cell, Marginal ZoneEpstein-Barr Virus Nuclear AntigensChromosomes, Human, 13-15Glutamate FormimidoyltransferaseGenes, mycProto-Oncogene Proteins c-mycB-LymphocytesEpstein-Barr Virus InfectionsLymphoma, Mantle-CellLymphoma, T-Cell, CutaneousHodgkin DiseaseLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, AnaplasticChromosomes, Human, Pair 14VincristineTumor Cells, CulturedGerminal CenterOncogenesAntibodies, Monoclonal, Murine-DerivedCyclophosphamideIn Situ Hybridization, FluorescenceAntigens, CD20Chromosomes, Human, 1-3Genes, Immunoglobulin Heavy ChainCell Line, TumorImmunophenotypingImmunoglobulin Heavy ChainsCell LineSesquiterpenes, GuaianeLeukemia, B-CellDoxorubicinGene RearrangementSesquiterpenes, EudesmaneChromosomes, Human, Pair 8NeprilysinCytogeneticsAntineoplastic Combined Chemotherapy ProtocolsLymphoma, Large-Cell, ImmunoblasticViral Matrix ProteinsHLA-A11 AntigenGenes, mybImmunohistochemistryGene Expression Regulation, NeoplasticProto-Oncogene Proteins c-bcl-2Genes, bcl-2PlasmacytomaCytarabineBase SequenceApoptosisAntibodies, MonoclonalTanacetum partheniumFlow CytometryVirus LatencyAntigens, ViralPrednisoneInhibitor of Differentiation ProteinsLymphoproliferative DisordersDNA, NeoplasmGenes, ImmunoglobulinChromosome BandingKaryotypingTreatment OutcomeMethotrexateReceptors, Antigen, B-CellCell Transformation, ViralNeoplasm ProteinsAntineoplastic AgentsEtoposideMolecular Sequence DataProto-OncogenesLeukemia, LymphoidPrognosisLymphocytesRemission InductionLymphoma, Extranodal NK-T-CellCell Transformation, NeoplasticTumor Markers, BiologicalTranscription, GeneticCell Line, TransformedPolymerase Chain ReactionGene Expression Regulation, ViralDNA, ViralChaperonin Containing TCP-1BiopsyHybrid CellsVirus ActivationNational Cancer Institute (U.S.)
ChemotherapyTumorsRajiHodgkinLymphocytesEndemic BurkittCellsGeneCancerBiopsyLeukemiaCauses Burkitt's lymphomaPathogenesisCell linesEPSTEIN-BARR-AfricaChildrenClinicalSymptomsPrimaryCurableInfectionBurkitt's LymphomaTumorAbstractMalignant lymphomaHigh-grade B-cell lymSporadic Burkitt lymphoma in adultsPathogenesisApoptosisHematologyIncidenceTumourCyclophosphamideVariant of Burkitt lymphomaAdults with Burkitt lymphomaSymptoms of Burkitt lymphomaChemotherapy for Burkitt lymphomaBone marrowTreat Burkitt lymphomaChildhood Burkitt lymphomaImmunodeficiency-associated BurkittAdultTreatmentCellOccursAssociated with the Epstein-BarrSubtypesAggressive lymphomaNewly diagnosedCommonlyDisease
Chemotherapy5
Tumors3
Raji2
  • METHODS: Here we report the cytotoxic effects of a synthesized conjugate of DZ with cisplatin (CIS) on B cell lymphoma CA46, Daudi, Namalwa, Raji, and Ramos cell lines in cell culture and in xenograft tumor formation. (kbco.hr)
  • The lectin depleted expression of mRNA coding multidrug resistant protein, MRP1, time- and dose-dependently through binding with Gb3 glycosphingolipid which is highly expressed on human Burkitt's lymphoma Raji cells. (yokohama-cu.ac.jp)
Hodgkin3
Lymphocytes2
Endemic Burkitt1
Cells2
Gene3
Cancer2
  • We found out 3 weeks ago, my daughter- in-law, who is about 6 months pregnant, has been taking multiple drugs which began with a cancer ( Burkitt s Lymphoma ) cure 3 yrs ago. (healthcaremagic.com)
  • 2019) 'Targeting Burkitt Lymphoma with a Tumor Cell-specific Heptamethine Carbocyanine-cisplatin Conjugate', Cancer , 125(13), pp. 2222-2232. (kbco.hr)
Biopsy1
  • A biopsy of the large abdominal mass was performed which confirmed that she had Burkitt lymphoma. (globalgiving.org)
Leukemia1
Causes Burkitt's lymphoma1
Pathogenesis1
Cell lines1
EPSTEIN-BARR-2
  • Background: The epidemiology of Burkitt Lymphoma (BL) shows that the endemic type is mainly confined to equatorial Africa and has a very close association with the Epstein-Barr virus (EBV), while the sporadic variant shows only a 20% association with EBV and is seen mainly in Europe and North America. (sun.ac.za)
  • Burkitt's lymphoma is also associated with an infection from the Epstein-Barr virus (EBV). (nicklauschildrens.org)
Africa1
  • Conclusions: The patients seen at Tygerberg Hospital, South Africa presented typically with the sporadic variant of Burkitt Lymphoma. (sun.ac.za)
Children3
Clinical2
Symptoms3
Primary1
  • A "SUEL-type lectin domain"(IPR000922) was described by Yasuhiro Ozeki in 1991 as with a unique primary structure for animal lectins with specificity to D-galactosides in the eggs of the sea urchin Anthocidaris crassispina (http://en.wikipedia.org/wiki/Galactose_binding_lectin_domain) . (yokohama-cu.ac.jp)
Curable1
Infection1
Burkitt's Lymphoma133
Tumor20
  • The tumor cells have a similar appearance to the cancer cells of classical endemic Burkitt lymphoma. (wikipedia.org)
  • Since Burkitt lymphoma and other B-cell lymphomas are a clonal proliferative process, all tumor cells from one patient are supposed to possess identical IgH genes. (wikipedia.org)
  • The tumor cells in Burkitt lymphoma generally strongly express markers of B cell differentiation (CD20, CD22, CD19), as well as CD10 and BCL6. (wikipedia.org)
  • The lymphoma is in only one place, either as a single tumor not in lymph nodes, or in lymph nodes in one part of the body (the neck, groin, underarm, etc. (cancer.org)
  • The lymphoma is more than one tumor and/or in more than one set of lymph nodes, all of which are either above or below the diaphragm (the thin breathing muscle that separates the chest and abdomen). (cancer.org)
  • But other factors can also affect a child's outlook, such as the location and size of the tumor(s), and how well the lymphoma responds to treatment . (cancer.org)
  • Burkitt lymphoma (BL) is a highly malignant B-cell tumor associated with Epstein-Barr Virus (EBV) infection. (hindawi.com)
  • The endemic variant of Burkitt lymphoma observed in equatorial Africa - a rapidly progressive jaw or orbital tumor - is the most common presentation, occurring more frequently in young children. (renalandurologynews.com)
  • The following chapter sheds light on epidemiology, tumor biology, treatment options and prognosis of this lymphoma which has evolved from an enigmatic syndrome to a curable disease. (springer.com)
  • A case of a so-called "Burkitt tumor" in a Dutch boy. (springer.com)
  • In the case of Burkitt's lymphomas (BL), most current evidence indicates that the tumor requires the virus minimally to block apoptosis. (pubmedcentralcanada.ca)
  • For both cervical carcinomas carrying human papillomaviruses (HPV) and Burkitt's lymphomas carrying Epstein-Barr virus (EBV), inhibiting viral genes in cell culture induces cell death in the tumor derived cells [ 8 - 10 ]. (pubmedcentralcanada.ca)
  • There are cases with poor outcome caused by toxic effects of the therapy, tumor lysis syndrome or metastatic spread of lymphomas to the central nervous system. (aacrjournals.org)
  • However, as lymphomas are known to form metastases in several sites, the analysis of their metastatic behavior and the suppression of this by imipramine-blue treatment may have implications for other aggressive tumor types as well. (aacrjournals.org)
  • Nevertheless, there are cases of poor clinical outcome caused by the toxicity of the intensive chemotherapy, tumor lysis syndrome, or metastatic spread of lymphoma cells to the central nervous system ( 4-7 ). (aacrjournals.org)
  • Here, we demonstrated for the first time the overexpression of DNMT1 and DNMT3B in Burkitt lymphoma (BL) tumor samples (69% and 86%, respectively). (sigmaaldrich.com)
  • The first broad genetic landscape map of a Burkitt lymphoma tumor has identified 70 mutations, including several not previously associated with cancer and a new one that is unique to the disease. (oncologynurseadvisor.com)
  • Dave explained that this alteration alone may not cause cancer, but when it occurs along with the MYC gene mutations that are common in Burkitt lymphoma and other malignancies, it works like an accelerant to fuel tumor growth. (oncologynurseadvisor.com)
  • Called also African lymphoma and Burkitt's tumor . (thefreedictionary.com)
  • The underlying mechanism of action of CDBPA in Burkitt`s lymphoma was tested in vitro and its effect on tumor size and survival was tested in a NOD-scid mice model. (omicsonline.org)
Abstract2
  • An abstract of the study "Insertion of IGH into MYC in Burkitt Lymphoma identified by sequential FISH on paraffin sections" is presented. (ebscohost.com)
  • Mark J. Roschewski, MD , of the National Cancer Institute, discusses phase II study findings that showed DA-EPOCH-R cures most adult patients with Burkitt lymphoma, irrespective of HIV status (Abstract 188). (ascopost.com)
Malignant lymphoma5
High-grade B-cell lym2
  • High-grade B-cell lymphoma that contains genetic changes that indicate the patient has a high risk of continued cancer growth. (mskcc.org)
  • Patients must have Burkitt lymphoma/leukemia or high-grade B-cell lymphoma that has continued to grow or came back despite prior treatment. (mskcc.org)
Sporadic Burkitt lymphoma in adults1
Pathogenesis3
Apoptosis6
  • Apoptosis resistance is the major cause of chemotherapy failure in most kinds of cancers, including Burkitt lymphomas (BL). (hu-berlin.de)
  • The reactivation of p16 and p14 in our model and our ability to inhibit cell proliferation and induce apoptosis through the Rb- and p-53 pathways opens new prospects for the understanding and treatment of Burkitt lymphoma. (oncologynurseadvisor.com)
  • Exposure to Sonic or Indian Hedgehog or cyclopamine (SMO inhibitor) does not modulate GLI1 expression, cell proliferation, or apoptosis in most Burkitt lymphoma cell lines. (luriechildrens.org)
  • Inhibition of GLI1 by GANT61 increases apoptosis and reduces viability of some Burkitt lymphoma cells. (luriechildrens.org)
  • Discovery of an Apoptosis Inducing Ligand for Burkitt Lymphoma" by Carolyn Laymon, Kyla Bradylong et al. (calpoly.edu)
  • We demonstrated that CDBPA significantly reduced cell viability and induced apoptosis via the extrinsic and the intrinsic apoptotic pathways of Burkitts lymphoma cells without causing cell cycle arrest but reduction of the various phases. (omicsonline.org)
Hematology1
  • J. Durig, W. Fiedler, M. de Wit, M. Steffen and D. Hossfeld, "Lactic Acidosis and Hypoglycemia in a Patient with High-Grade Non-Hodgkin's Lymphoma and Elevated Circulating TNF-a," Annals of Hematology, Vol. 72, No. 2, 1996, pp. 97-99. (scirp.org)
Incidence8
  • Rising incidence HIV is expected to augment growth of the Burkitt lymphoma treatment market, as Burkitt lymphoma is an AIDS-defining cancer that is expected to occur more frequently in people suffering from HIV than in the general population. (coherentmarketinsights.com)
  • No unusual local patterns of leukemia, lymphoma, or infectious mononucleosis incidence were found, and no other persons with childhood cancer were identified as having been in contact with the patients or being in their particular neighborhood. (cdc.gov)
  • In this type of Burkitt lymphoma, the peak incidence of infection is between the ages of 4 and 7. (uexpress.com)
  • The most common type of Burkitt lymphoma in the United States is much rarer -- about three cases per million people per year -- and the peak incidence is about 11 years of age, with the majority of cases occurring in people younger than 35. (uexpress.com)
  • In developed countries where sporadic cases are most commonly encountered, Burkitt lymphoma can occur at any age, although the peak incidence is in the first decade of life. (renalandurologynews.com)
  • Meningeal involvement in non-Hodgkin's lymphoma: symptoms, incidence, risk factors and treatment. (springer.com)
  • Burkitt lymphoma is a rare disease with an incidence rate of approximately 0.2, which means that 2 individuals within a population of 1 million are affected by Burkitt lymphoma per year ( 2 ). (aacrjournals.org)
  • Because of the low incidence of the disease, research on novel drugs for Burkitt lymphoma treatment proceeds only slowly. (aacrjournals.org)
Tumour5
  • Tumour lysis syndrome (TLS) is a group of side effects that develops when a large number of lymphoma cells are killed in a short period of time. (cancer.ca)
  • BL belongs to the non-Hodgkin lymphomas group, and is the first human tumour undoubtedly related to a viral origin (Epstein-Barr virus). (biomedsearch.com)
  • Background: Burkitt lymphoma (BL) is the commonest tumour among Nigerian children. (who.int)
  • 1 BL tumour cells usually express IgM, 13 - 15 B-cell markers such as CD19, CD20 and CD22 and markers of germinal centre (GC) centroblasts such as CD10, BCL6 4 and the human germinal centre-associated lymphoma (HGAL) protein. (bmj.com)
  • Letter: childhood lymphoma resembling Burkitt's tumour in the southern Argentine. (bmj.com)
Cyclophosphamide1
Variant of Burkitt lymphoma1
Adults with Burkitt lymphoma3
Symptoms of Burkitt lymphoma1
  • What are the symptoms of Burkitt lymphoma? (webmd.com)
Chemotherapy for Burkitt lymphoma1
Bone marrow9
Treat Burkitt lymphoma2
  • Rituximab (Rituxan) is the most common targeted therapy used to treat Burkitt lymphoma. (cancer.ca)
  • Intrathecal chemotherapy may be given to prevent the spread of Burkitt lymphoma to the brain and spinal cord (called the central nervous system, or CNS) or to treat Burkitt lymphoma that has spread to the CNS. (cancer.ca)
Childhood Burkitt lymphoma3
Immunodeficiency-associated Burkitt4
  • Immunodeficiency-associated Burkitt lymphoma is usually associated with HIV infection or occurs in the setting of post-transplant patients who are taking immunosuppressive drugs. (wikipedia.org)
  • Immunodeficiency-associated Burkitt lymphoma may demonstrate more plasmacytic appearance or more pleomorphism, but these features are not specific. (wikipedia.org)
  • Immunodeficiency-associated Burkitt lymphoma tends to occur in people with weakened immune systems, typically those with HIV infection. (cancer.ca)
  • The number of cases of immunodeficiency-associated Burkitt lymphoma seems to be dropping because antiretroviral therapy is used to treat HIV. (cancer.ca)
Adult6
Treatment10
Cell19
Occurs3
Associated with the Epstein-Barr1
Subtypes3
Aggressive lymphoma2
Newly diagnosed1
Commonly2
Disease4
  • If Burkitt lymphoma is suspected, all or part of an enlarged lymph node or other suspicious disease site will be biopsied. (webmd.com)
  • Stage I and II lymphomas are usually considered limited-stage disease and are treated the same way. (cancer.org)
  • Stage III and IV lymphomas are usually thought of as advanced-stage disease and are also treated alike. (cancer.org)
  • And the second point is that even though you succeed in treating properly elderly patients, the fraction of long survivors is lower and this is probably due to a different biology of disease when this type of lymphoma arises in a patient who is older than 65. (ecancer.org)
Burkitt's Lymphoma | Definition of Burkitt's Lymphoma by Merriam-Webster
Burkitt's Lymphoma | Definition of Burkitt's Lymphoma by Merriam-Webster (merriam-webster.com)
Burkitt Lymphoma and Burkitt-like Lymphoma: Practice Essentials, Background, Etiology and Pathophysiology
Burkitt Lymphoma and Burkitt-like Lymphoma: Practice Essentials, Background, Etiology and Pathophysiology (emedicine.medscape.com)
Reports on Cure 250 Children with Burkitt Lymphoma in Africa - GlobalGiving
Reports on Cure 250 Children with Burkitt Lymphoma in Africa - GlobalGiving (globalgiving.org)
5 Home Remedies For Burkitt Lymphoma - Natural Home Remedies & Supplements
5 Home Remedies For Burkitt Lymphoma - Natural Home Remedies & Supplements (natural-homeremedies.com)
Burkitt's lymphoma - Wikipedia
Burkitt's lymphoma - Wikipedia (en.wikipedia.org)
Incredible transformation of cancer teen with facial tumour whose own mother disowned him
Incredible transformation of cancer teen with facial tumour whose own mother disowned him (thesun.co.uk)
Burkitt Lymphoma by Aislynn Kennedy on Prezi
Burkitt Lymphoma by Aislynn Kennedy on Prezi (prezi.com)
Material Search Results
Material Search Results (merlot.org)
Background
Background (people.virginia.edu/~jcb2g/)
Molecular definition of Burkitt lymphoma | News articles | News and Events | About us | University of Groningen
Molecular definition of Burkitt lymphoma | News articles | News and Events | About us | University of Groningen (rug.nl)
Research | Genome Sciences Centre
Research | Genome Sciences Centre (bcgsc.ca)
Our Achievements Timeline | Cancer Research UK
Our Achievements Timeline | Cancer Research UK (cancerresearchuk.org)
Adult Non-Hodgkin Lymphoma Treatment (PDQ®)-Patient Version - National Cancer Institute
Adult Non-Hodgkin Lymphoma Treatment (PDQ®)-Patient Version - National Cancer Institute (cancer.gov)
Https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq
Https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq (cancer.gov)
What is MALT Lymphoma? - Opposing Views
What is MALT Lymphoma? - Opposing Views (opposingviews.com)
Blood cancer research
Blood cancer research (leukaemia.org.au)
Artikelen in 'Nature' en 'Science' | Toponderzoek | Onderzoek | Rijksuniversiteit Groningen
Artikelen in 'Nature' en 'Science' | Toponderzoek | Onderzoek | Rijksuniversiteit Groningen (rug.nl)
Screening may miss pre-cancerous anal lesions in women with HIV | aidsmap
Screening may miss pre-cancerous anal lesions in women with HIV | aidsmap (aidsmap.com)
September 2007 - Volume 29 - Issue 9 : Journal of Pediatric Hematology/Oncology
September 2007 - Volume 29 - Issue 9 : Journal of Pediatric Hematology/Oncology (journals.lww.com)
Aidsmap
Aidsmap (aidsmap.com)
1-99<...
1-99<... (pedrad.org)
Lymphoma Subtypes - Lymphoma Coalition
Lymphoma Subtypes - Lymphoma Coalition (lymphomacoalition.org)
Molecular Genetics in the Diagnosis of Lymphoid Neoplasms
Molecular Genetics in the Diagnosis of Lymphoid Neoplasms (medscape.com)
Hepatitis B Virus and Risk of Non-Hodgkin Lymphoma
Hepatitis B Virus and Risk of Non-Hodgkin Lymphoma (medscape.com)
HIV-associated Hematological Malignancies | SpringerLink
HIV-associated Hematological Malignancies | SpringerLink (link.springer.com)
Burkitt lymphoma: MedlinePlus Medical Encyclopedia
Burkitt lymphoma: MedlinePlus Medical Encyclopedia (medlineplus.gov)
HIV/AIDS denialist Christine Maggiore is dead | ScienceBlogs
HIV/AIDS denialist Christine Maggiore is dead | ScienceBlogs (scienceblogs.com)
Viral Infections of Humans | SpringerLink
Viral Infections of Humans | SpringerLink (link.springer.com)
Non-Hodgkin's Lymphoma: Types, Treatment, Symptoms , Stages & Survival Rate
Non-Hodgkin's Lymphoma: Types, Treatment, Symptoms , Stages & Survival Rate (medicinenet.com)